NHS to Offer Long-Acting HIV Prevention Injection, Aiming for 2030 Eradication Goal
A groundbreaking HIV prevention injection is set to be rolled out by the National Health Service (NHS) in England and Wales, bringing the region in line with existing policy in Scotland. This long-acting shot, administered six times a year or every other month, provides a crucial alternative to daily oral medication for individuals at risk of contracting the virus.
The new preventative measure, cabotegravir (CAB-LA), is expected to significantly contribute to the United Kingdom’s ambitious goal of eliminating new HIV cases by 2030. Promising early data also suggests a potential future with an even less frequent preventative regimen, with research indicating the possibility of an annual HIV prevention jab utilizing lenacapavir.
“The approval of this game-changing injection perfectly embodies what this government is determined to deliver – cutting-edge treatments that save lives and leave no one behind,” stated Wes Streeting, the Secretary of State for Health and Social Care. “For vulnerable people who are unable to take other methods of HIV prevention, this represents hope.”
PrEP and the Challenges of Daily Medication
The injection builds upon existing PrEP (pre-exposure prophylaxis) therapy, a method where HIV-negative individuals take medication to reduce their risk of infection. While daily PrEP pills have proven highly effective, adherence can be a significant hurdle. Access can be difficult, the regimen impractical, or the experience simply embarrassing for some. Concerns about privacy – such as family members discovering medication – and the challenges faced by individuals experiencing homelessness or domestic violence can all impede consistent daily use.
The convenience and discretion offered by a long-lasting injection directly addresses these barriers.
Understanding HIV and the Importance of Prevention
HIV is a virus that attacks the immune system, weakening the body’s ability to fight off infections and diseases. Transmission occurs through unprotected sexual contact, sharing needles, or from mother to child during birth. It is crucial to note that cabotegravir, like other preventative measures, should be used in conjunction with safer sex practices, including consistent condom use.
The NHS has secured an undisclosed discount from the manufacturer, despite the treatment carrying a list price of approximately £7,000 per patient annually. The injection will be available to adults and adolescents with a healthy weight who are at high risk of sexually acquired HIV and eligible for PrEP, but for whom taking daily oral medication presents challenges. Approximately 1,000 individuals are expected to initially benefit from this new preventative option.
Access will be provided through NHS-operated sexual health clinics “in coming months,” according to the National Institute for Health and Care Excellence (NICE). However, charities are urging a swift rollout, citing existing long waiting times for clinic appointments.
Richard Angell, of the Terrence Higgins Trust, emphasized the need to expand access beyond traditional sexual health clinics. “It’s highly effective and acceptable for patients, and a vital tool for tackling inequalities – with the potential to reach those who are not currently accessing other HIV prevention.”
Addressing Disparities in PrEP Access
Official figures from England reveal a growing number of individuals utilizing PrEP services. Last year, 146,098 HIV-negative individuals accessing sexual health services were identified as needing PrEP due to substantial risk of HIV acquisition. Of those, approximately 76% (111,123) initiated or continued PrEP – a 7.7% increase from the previous year.
However, access to PrEP remains inequitable. Uptake is highest among white (79.4%) and ethnic minority (77.8%) gay, bisexual, and men who have sex with men. Conversely, uptake is significantly lower among Black African heterosexual women (34.6%) and men (36.4%). This disparity underscores the need for targeted outreach and tailored interventions to ensure equitable access to preventative care.
Alongside the introduction of the new injection, HIV testing has been expanded across 89 hospital A&E departments in England, routinely testing individuals undergoing blood work, particularly in areas with high HIV prevalence. This broadened testing initiative aims to identify and connect more individuals with preventative services.
